Key result
GPVI-targeted antithrombotic strategies demonstrate a safe profile in healthy volunteers without bleeding complications, supporting their further development for thromboembolic disorders.
Answers are grounded in this paper and cite their sources.
GPVI-targeted antithrombotic strategies show a promising safety profile, warranting further clinical investigation for thromboembolic disorders.
How both strategies targeting GPVI will compare in a real-life thrombotic settings remains to be seen and warrants additional clinical investigation.Yet, the safe profile of both compounds in healthy volunteers and the absence of bleeding complications in patients with a genetic deficiency of GPVI is encouraging for further development of GPVI-targeted antithrombotic strategies.
No takes yet. Share an insight, caveat, or question.
Denorme et al. (2019) studied this question. GPVI-targeted antithrombotic strategies demonstrate a safe profile in healthy volunteers without bleeding complications, supporting their further development for thromboembolic disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: